Immuron Limited has inked an exclusive US distribution deal for PROIBS®, a European-certified medical device targeting abdominal discomfort, marking a key step in its digestive health portfolio growth.
- Exclusive US distribution agreement with Calmino group AB
- PROIBS® addresses abdominal pain, bloating, and bowel irregularities
- Product backed by a large usability study with high user satisfaction
- PROIBS® has over a decade of presence in European markets
- Immuron leverages PROIBS® alongside Travelan® in US expansion
Immuron Targets $4.16 Billion US Digestive Health Market
Immuron Limited (ASX:IMC, NASDAQ: IMRN) has taken a decisive step to broaden its footprint in the lucrative US digestive health sector by securing exclusive distribution rights for PROIBS® from Swedish life sciences firm Calmino group AB. The US market for digestive and gut health supplements is valued at US$4.16 billion, and Immuron is positioning PROIBS® to capture a meaningful slice of this opportunity.
PROIBS® is a medical device designed to alleviate abdominal pain, bloating, and irregular bowel movements such as diarrhoea and constipation. Its active component, AVH200®, is derived from Aloe barbadensis Mill and supports the intestinal mucosal barrier through gel-forming properties. The product’s safety profile is robust, with no known interactions with other medications, making it suitable for long-term use.
Strong User Endorsement and European Track Record
Calmino group AB has marketed PROIBS® in European pharmacies for over a decade, establishing a credible track record. A usability study involving 1,003 users found that 94% reported PROIBS® was helpful, 91% noted improvements in daily life, and an overwhelming 98% would recommend it to others. This data provides Immuron with a solid evidence base to promote the product confidently in the US.
Flavio Palumbo, Immuron’s Chief Commercial Officer, highlighted the strategic fit of PROIBS® within the company’s digestive health portfolio, which already includes Travelan®, a product experiencing rapid US sales growth. Palumbo emphasised the scientific backing and physician endorsements behind PROIBS®, underlining its potential to improve quality of life for sufferers of digestive ailments.
Building on Australian Launch and Transcontinental Partnership
Immuron first introduced PROIBS® to the Australian market during FY26. The US launch marks an important next phase in the partnership with Calmino group AB, which Tobias Kisker, Calmino’s CEO and founder, described as evolving into a multi-continent collaboration. The agreement reflects a shared ambition to leverage established products with proven efficacy across new geographies.
This move aligns with Immuron’s broader commercial growth strategy, which has recently delivered a 6% revenue increase to AUD 7.7 million, supported by expanding sales in North America and Canada despite currency headwinds. The company’s ability to secure FDA approvals and develop innovative oral therapeutics further bolsters its expansion credentials.
Bottom Line?
Immuron’s exclusive US distribution deal for PROIBS® signals a strategic push into a sizable market segment, but the impact will hinge on execution and market reception amid competitive digestive health products.
Questions in the middle?
- How will PROIBS® sales perform against established US digestive health brands?
- What marketing and distribution channels will Immuron prioritise for PROIBS® in the US?
- Could the partnership with Calmino group AB lead to further product launches or geographic expansion?